Sharps Technology Stock Doubles After $400 Million Solana Treasury Plan

Medical device manufacturer Sharps Technology (NASDAQ: STSS) stunned investors this week after revealing a bold pivot into digital assets. The company revealed a $400 million Solana-based treasury strategy, sending its stock soaring nearly 96% in a single trading day. The move signals yet another example of non-crypto firms embracing blockchain assets to diversify reserves and court institutional attention.

Stock Price Surge Follows Treasury

On Monday, Sharps shares surged to an intraday high of $14.53, nearly doubling from Friday’s close of $7.40. The stock later settled at $12.01, still a dramatic gain of more than 60% in one day.

The rally was fueled by Sharps’ reveal of a private placement deal and a new partnership with the Solana Foundation to acquire SOL, the blockchain’s native token. Market sentiment shifted swiftly on Stocktwits, where retail traders upgraded their outlook on Sharps from “bullish” to “extremely bullish” within 24 hours.

Details of the $400M Solana Treasury Strategy

Sharps confirmed that it signed a letter of intent with the Solana Foundation to purchase $50 million worth of SOL tokens through a private investment in public equity (PIPE) transaction. Under this structure:

• Accredited investors will buy company stock bundled with stapled warrants at $6.50 per unit.

• Warrants will be exercisable at $9.75 over three years.

• The equity offering directly links Sharps’ performance to Solana’s token price trajectory.

The broader treasury plan, valued at $400 million, will give Sharps one of the largest Solana holdings among publicly traded companies.

New Leadership to Drive the Crypto Pivot

To spearhead its digital treasury strategy, Sharps appointed Alice Zhang, co-founder of Web3 startup Jambo, as its Chief Investment Officer. Zhang emphasized that Solana adoption is accelerating worldwide, calling the treasury pivot a move designed to secure “long-term success.”

In addition, James Zhang, a respected Solana ecosystem adviser, has been appointed as strategic adviser to guide treasury management and ensure the plan aligns with Solana’s long-term vision.

Why Solana?

Solana has emerged as one of the most institutionally supported blockchains in 2025. Known for its low-cost, high-speed transactions, the network is increasingly favored by enterprises. Even Visa has begun testing Solana’s blockchain to settle global credit card transactions faster than traditional systems.

With SOL trading around $187-$189—down slightly from its weekend high of $212—Sharps is entering during a period of price pullback, which some investors view as a strategic entry point. Solana’s all-time high remains $293, reached in January 2025.

Healthcare Firms Joining the Crypto Treasury Trend

Sharps’ pivot isn’t happening in isolation. Several healthcare and biotech firms have recently integrated crypto assets into their treasuries:

• Hoth Therapeutics allocated $1 million in Bitcoin in November 2024.

• Atai Life Sciences followed in March with a $5 million Bitcoin purchase.

• 180 Life Sciences rebranded to ETHZilla in July, unveiling a $425 million Ether treasury after its stock collapsed by 99%.

These moves illustrate a broader trend: smaller-cap healthcare companies seeking growth and stability are increasingly turning to crypto treasuries to diversify reserves and attract investor interest.

Wall Street Voices Caution

Despite investor enthusiasm, analysts are cautious. In a recent educational video, Charles Schwab warned that companies allocating large portions of their reserves to volatile cryptocurrencies may be raising “red flags.”

The risks are clear: crypto prices remain highly volatile, and aligning a company’s treasury with digital assets outside its core business model could expose shareholders to unpredictable swings.

Still, Sharps insists its pivot is strategic rather than speculative. By linking equity offerings to Solana and securing institutional partnerships, the company argues it is positioning itself for higher long-term returns compared to holding traditional reserves.

Institutional Support Could Mitigate Risks

Sharps’ strategy also benefits from growing institutional adoption of Solana. Unlike many altcoins, Solana has attracted support from major investment firms, payment networks, and decentralized finance builders. This institutional layer provides liquidity and credibility that could reduce some of the volatility risks flagged by Wall Street.

The appointment of experienced Web3 executives like Alice Zhang further strengthens investor confidence that Sharps has the expertise to manage this transition.

Looking Ahead

The offering is expected to close on or around August 28, with accredited investors funding allocations in either locked or unlocked SOL. Participants will receive pre-funded and stapled warrants, deepening the link between Sharps’ equity and Solana’s token performance.

If successful, Sharps will join the ranks of public companies making outsized bets on digital assets, potentially reshaping its market identity from a traditional medical device maker into a hybrid healthcare–crypto treasury firm.

Whether this pivot proves visionary or reckless remains to be seen, but one thing is clear: Sharps Technology has thrust itself into the spotlight at the intersection of biotech and blockchain finance.